Print   



NextGen Group Plc

('NextGen' or 'the Company')

Result of Annual General Meeting and Board Changes

 

NextGen Group plc announces that at the Company's Annual General Meeting, which was held this morning, all the resolutions proposed were duly passed. 

Following shareholder approval at the AGM, Mr Leif Hamø has now been appointed as Finance Director of the Company and the other board changes, details of which were set out in in the notice of AGM, have also taken effect.

Mr. Hamø has more than 20 years experience in the financial and biotech sector and has held several board positions within financial and biotech companies. From 2002 to 2009, Mr. Hamø was the Chief Financial Officer of TopoTarget A/S, a cancer drug biotech company listed on the NASDAQ OMX and the Copenhagen stock exchange. Before this role Mr. Hamø was Chief Executive Officer of AcceptFinance A/S, a Danish credit card company. Mr. Hamø has a BSc in Economics and Business Administration and a Graduate Diploma in Business Administration, Finance, Organisation and Management.

Disclosures under Schedule 2 of the AIM Rules

Leif Schimmell Hamø, aged 64, is or has been a director of the following companies during the previous five years:

Current directorships:

DK Byggeri ApS

Hamø ApS

Directorships held within the previous five years:

TopoTarget USA Inc.

TopoTarget Germany

Prolifix Ltd

There are no other matters which are required to be announced with regard to this appointment under paragraph (g) of Schedule 2 of the AIM Rules.

For further details please contact: 

 

NextGen Group 

Klaus Rosenau, Chairman

+49 160 5516756

Seymour Pierce 

Jonathan Wright, Nicola Marrin 

+44 20 7107 8000 

 

About NextGen 

NextGen (AIM: NGG), the biomarker specialists, provide services to pharmaceutical and biotech companies globally. Using advanced techniques, such as Multiple Reaction Monitoring (MRM) mass spectrometry analysis, the Company is developing a portfolio of robust assays for testing clinical samples for drug safety and efficacy, and the development of personalized treatment for patients. NextGen Sciences' range of services, which include biomarker testing, discovery and assay development, are employed by its customers as a key part of the biomarker-based drug and diagnostic development process. For more information visit www.nextgensciences.com 

NextGen Group PLC floated on the AIM market in London in December 2005 raising £2.4 million in an oversubscribed offering which included strong institutional investor support from Germany as well as in the UK. Further details relating to NextGen Group PLC and its products can be found at www.nextgensciences.com

---

ENDMSCUBRVRKKRBUAR